Author:
Usher Cara,McCullagh Laura,Tilson Lesley,Barry Michael
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference22 articles.
1. Office of Inspector General. United States Department of Health and Human Services. The Orphan Drug Act implementation and impact. 2001.
http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf
.
2. European Medicines Agency. Orphan Designation. 2017.
https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview
. Accessed Feb 2019.
3. Orphan incentives. European Medicines Agency.
https://www.ema.europa.eu/en/humanregulatory/research-development/orphan-designation/orphan-incentives
. Accessed Mar 2019.
4. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA. Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18(6):906–14.
5. Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012;15(8):1182–4.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献